文献速递白内障与屈光手术

白内障手术中未使用药品的成本与潜在环境影响的量化研究

Quantification of the Cost and Potential Environmental Effects of Unused Pharmaceutical Products in Cataract Surgery.
PubMed 文献 · JAMA Ophthalmol · 2019-01-01

这项描述性定性研究纳入美国东北部4个手术中心,测量超声乳化术后剩余药品的体积或重量,并估算财务与环境成本。结果显示所有中心每月平均45.3%的药品未被使用,每中心年未使用药品成本估计约195200美元,并产生不必要的碳排放、空气污染和富营养化潜力。作者认为若这些发现能被证实并在美国或其他地区具有普遍性,减少这些成本可能有价值。

要点

  • 4个中心共调查116种独特药品,每月平均45.3%的药品按重量或体积未被使用。
  • 每中心年未使用药品成本估计约195200美元。
  • 各中心每月不必要的潜在碳排放为418至2498 kg CO2-e。

核心结论

  • 本研究提示超声乳化过程中未使用的药品导致相对较高的财务和环境成本。
  • 若这些发现能被证实并在美国或其他地区具有普遍性,减少这些成本可能有价值。

研究设计与样本

  • 描述性定性研究,纳入美国东北部4个手术点:一家私人门诊手术中心、一家私人三级医疗中心、一家私人门诊中心和一家联邦运营的退伍军人医疗中心。
  • 价格与服务/药品使用数据获取时段:三级医疗中心和门诊中心为2016年1月1日至4月30日;门诊手术中心为2017年6月1日至2018年3月31日;联邦医疗中心为2017年11月1日至2018年2月28日。
  • 数据收集自无玻璃体丢失或其他并发症的常规超声乳化手术,测量术后剩余药品的体积或重量,计算每例和每月药品总成本与平均成本。
  • 环境影响采用经济投入产出生命周期评估方法估算;数据分析时间为2017年12月1日至2018年6月30日。

主要发现

  • 4个中心共调查116种独特药品;假设未测量的药品无材料剩余,所有中心每月累计平均183304 mL中有83070 mL(45.3%)的药品按重量或体积未被使用。
  • 每中心年未使用药品成本估计约195200美元。
  • 按体积计算,滴眼液未使用比例为65.7%,注射剂为24.8%,全身用药为59.9%。
  • 门诊手术中心每月未使用量65.9%(83440 mL中54971 mL),三级医疗中心21.3%(80344 mL中17143 mL),联邦医疗中心38.5%(689 mL中265 mL),门诊中心56.8%(18832 mL中10691 mL)。
  • 各中心每月不必要的潜在碳排放分别为2135、2498、418和711 kg CO2-e;不必要的潜在空气污染各中心间为0.8至4.5 kg PM10-e/月,不必要的富营养化潜力各中心间为0.07至0.42 kg N-e/月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pharmaceutical products, including unused portions, may contribute to financial and environmental costs in the United States. Because cataract surgery is performed millions of times each year in the United States and throughout the rest of the world, understanding these financial and environmental costs associated with cataract surgery is warranted. OBJECTIVE: To investigate the financial and environmental costs of unused pharmaceutical products after phacoemulsification surgery. DESIGN, SETTING, AND PARTICIPANTS: This descriptive qualitative study included 4 surgical sites in the northeastern United States (a private ambulatory care center, private tertiary care center, private outpatient center, and federally run medical center for veterans). Prices and data for use of services and pharmaceuticals were obtained for the tertiary care and outpatient centers from January 1 through April 30, 2016; for the ambulatory care center from June 1, 2017, through March 31, 2018; and the federal medical center from November 1, 2017, through February 28, 2018. Data were collected from routine phacoemulsification surgical procedures without vitreous loss or other complications. Volume or weight of medications remaining after surgery was measured. Total and mean costs of medications per case and month were calculated. Environmental effects were estimated using economic input-output life cycle assessment methods. Data were analyzed from December 1, 2017, through June 30, 2018. MAIN OUTCOMES AND MEASURES: Cost of unused pharmaceutical products (in US dollars) and kilogram equivalents of carbon emissions (carbon dioxide [CO2-e]), air pollution (fine particulate matter emissions of ≤10 μm in diameter [PM10-e]), and eutrophication potential (nitrogen [N-e]). RESULTS: A total of 116 unique drugs were surveyed among the 4 centers. Assuming unmeasured medications had no materials left unused, a cumulative mean 83 070 of 183 304 mL per month (45.3%) of pharmaceuticals were unused by weight or volume across all sites. Annual unused product cost estimates reached approximately $195 200 per site. A larger percentage of eyedrops (65.7% by volume) were unused compared with injections (24.8%) or systemic medications (59.9%). Monthly unused quantities at the ambulatory care center (65.9% by volume [54 971 of 83 440 mL]), tertiary care center (21.3% [17 143 of 80 344 mL]), federal medical center (38.5% [265 of 689 mL]), and outpatient center (56.8% [10 691 of 18 832 mL]) resulted in unnecessary potential emissions at each center of 2135, 2498, 418, and 711 kg CO2-e/mo, respectively. Unnecessary potential air pollution between sites varied from 0.8 to 4.5 kg PM10-e/mo, and unnecessary eutrophication potential between sites varied from 0.07 to 0.42 kg N-e/mo. CONCLUSIONS AND RELEVANCE: This study suggests that unused pharmaceutical products during phacoemulsification result in relatively high financial and environmental costs. If these findings can be substantiated and shown to be generalizable in the United States or elsewhere, reducing these costs may be of value.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Tauber J, Chinwuba I, Kleyn D, et al. Quantification of the Cost and Potential Environmental Effects of Unused Pharmaceutical Products in Cataract Surgery. JAMA Ophthalmol. 2019. PMID: 31369052. doi:10.1001/jamaophthalmol.2019.2901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。